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ABSTRACT 
Background 
Malaria is a health, social and economic burden in Nigeria and consistently ranks 
amongst the four most common causes of childhood deaths. Treatment of malaria is 
usually started at home; care is only sought from the health facility when the treatment is 
ineffective (McCombie, 1996). Patent medicine vendors (PMVs) have been identified as 
a widely patronized source for drugs used in the home treatment of malaria (Breiger et al, 
2001; Goodman, et al, 2007; Salako et al, 2001). Inadequate or poor knowledge and 
practices in the use of anti-malaria drugs (AMDs) increases morbidity and mortality, 
undermines therapeutic efficacy, and promotes the emergence and spread of drug-
resistant malaria.  
Aim 
The aim of the study was to describe and quantify the knowledge and self-reported 
practices of PMVs in the use of antimalarials, particularly artemisinin-based combination 
therapies (ACTs), in a poor  urban community in Lagos state, Nigeria 
Methods  
The study was a cross-sectional, descriptive study of the knowledge and self-reported 
practices of patent medicine vendors in the usage of ACTs in an urban community in 
Lagos. All eligible vendors were interviewed between 18th August and 9th September, 
2008. A structured questionnaire was used to collect demographic information, 
knowledge of malaria, ACT anti-malaria treatment policy and the usage of ACTs. These 
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self-reported practices were assessed in terms of conformity with the ACT policy. Data 
was analysed using Epi info. 
 
Results  
A total of 105 Patent Medicine Vendors were interviewed (92% response rate). The study 
showed that they had a high knowledge of the symptoms of uncomplicated malaria; 
however recognition of severe malaria was poor.  Awareness of the ACT Anti-malaria 
Policy was high, but understanding and application seemed to be weak. Knowledge of 
what constitutes an ACT was poor, with only 14% correctly identifying two ACTs 
Additionally, 40% vendors were willing to break or share the pack of ACT during sale, 
potentially selling an inappropriate dose. The vendors engaged in practices that were 
contrary to the policy; 55% and 71% were still selling chloroquine and sulfadoxine-
pyrimethamine, respectively, for malaria treatment. Medicine vendors who had higher 
education qualifications were more likely to be aware of the policy (Fisher’s exact test 
0.0138) and to ask for the specific age of the patient (p-value 0.0096, OR 4.7744). 
Vendor who had been trained on the policy were less likely to use chloroquine in the 
treatment of malaria. 
Conclusions and Recommendations 
Knowledge of the ACT Malaria Policy was high, but reported practices were 
unsatisfactory. Vendors should to be trained and provided with health education 
information on the policy to improve knowledge and practices.  Stricter regulatory 
control by the Pharmacists’ Council of Nigeria (PCN) and the National Agency for Food 
and Drug Administration and Control (NAFDAC) is required to improve adherence to the 
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Policy. In addition, community health education and re-orientation, is required to inform 
mothers/care givers to request ACTs for the treatment of malaria. 
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CHAPTER 1: INTRODUCTION 
1.1: Background 
 
Malaria is a major cause of illness and death in Nigeria and exerts significant pressure on 
the economy and the poor. It is responsible for 30% of all childhood deaths, 11% of 
maternal deaths, 50% of all out-patient attendances (Pediatric Association of Nigeria, 
PAN, 1994) and 70% of out-patient attendances of children under 5 years of age (Federal 
Ministry of Health, FMOH, 2001). This data is mainly based on clinical diagnosis of 
malaria.  Recent estimates by the World Health Organisation WHO (2007) report that 
over 40% of the world’s population, especially those living in the poorest countries such 
as Nigeria are at risk of malaria. Annually, over 500 million people become ill with 
malaria and most of the cases and deaths are in sub-Saharan Africa. Approximately 85% 
of malaria cases and 90% of malaria related deaths are recorded in Africa (Bremen, Egan 
& Keutsch, 2007). 
 
Early, effective case management is one of the cornerstones of malaria control and access 
to diagnosis and effective anti-malaria treatment has been identified as crucial in reducing 
morbidity and mortality from malaria (FMOH, 2001;WHO, 2000;). Home management 
of malaria is popular and widespread; evidence from studies has shown that more than 
70% of malaria episodes in rural areas and over 50% in urban areas are home treated 
(McCombie, 1996). Reports of surveys across Africa have shown that between 15-83% 
of mothers/caregivers utilize the informal private sectors, such as the patent medicine 
vendors (PMVs) as sources of drugs for childhood illnesses, including fever and malaria. 
(Biritwum et al, 2000; Ene-Obong et al, 2000; Hamel et al, 2001; Salako et al, 
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2001;Tsuyouk et al, 2001). The National Malaria Situation Analysis conducted in Nigeria 
in 2001 reported that 60% of mothers/caregivers use patent medicine vendors as the 
primary source of drugs in the home treatment or self treatment of malaria (FMOH, 
2005a). 
 
Patent medicine vendors are traders without formal pharmacy training, licensed to sell 
non-prescription medicines such as anti-malarial drugs. They have also been reported to 
be a major source of health information to the communities that they serve (Salami & 
Breiger, 2005). However, concerns have often been expressed about their knowledge, 
practices and the quality of care they provide. In 2005, Nigeria changed to artemisinin-
based combination therapies (ACTs) for the treatment of malaria, with full 
implementation in 2006. ACTs were re-classified as over the counter (OTC) drugs and so 
patent medicine vendors can now legally stock and sell these anti-malarial drugs.  
 
1.2: Problem Statement   
Malaria is often inappropriately treated, which impedes control causing significant 
morbidity and mortality. In Sub-Sahara Africa mothers/care givers of children usually 
start treatment of malaria based on advice and medicines obtained from patent medicine 
vendors. Patent medicine vendors are a widely patronized source for home management 
of fevers and malaria illness especially in children and have also been reported to be a 
major source of health information to the communities that they serve (Salami & Breiger, 
2005). In 2005, Nigeria changed to the artemisinin-based combination therapy (.ACT) for 
malaria treatment, with full implementation in 2006 when ACTs were re-classified as 
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OTC drugs.  With the new policy, there are a number of concerns regarding the practices 
of patent medicine vendors, including that they may continue to sell the artemisinin alone 
or sell the component tablets individually (known as monotherapy) and eventually 
undermine the artemisinin-based combination therapy efficacy (Goodman, et al 2007); 
that they may not supply the correct dosage and full course of treatment; and they may 
not store ACTs correctly. Strategies for improving practice require accurate information 
about current practices and usage patterns of these anti-malarial drugs. This study will 
explore the knowledge and practices of the patent medicine vendors in the treatment of 
malaria in relation to the new anti-malaria Treatment Policy. 
 
1.3: Context and setting 
The city of Lagos lies in the South Western part of Nigeria on the Atlantic coast in the 
Gulf of Guinea. It is the fastest growing city in Nigeria and most economic and industrial 
activities takes place here. As with most large cities in developing countries, while there 
are districts with considerable wealth, many residents live in slums such as Mushin 
(Breiger, et al 2001). The study will be carried out in Mushin, a densely populated area, 
inhabited by low income and socio-economically disadvantaged population. According to 
the 2006 census Lagos has a population of 17,552,942 inhabitants while Mushin has a 
population of 1,321,517. (Lagos, 2008). The main economic activity is petty trading. 
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CHAPTER 2: LITERATURE REVIEW 
2.1: Malaria Infection and Diagnosis 
Malaria is an infectious disease caused by the parasite of the genus Plasmodium which is 
spread through the bite of infected, female anopheles mosquitoes. Malaria presents with a 
wide range of signs and symptoms such as fever, malaise, fatigue, lassitude, headache, 
dizziness, anorexia, nausea, vomiting and, in severe cases, anaemia, jaundice, 
convulsions, and prostration.  Clinical diagnosis of malaria is difficult as the clinical 
features are non-specific and may be confused with many other diseases. Generally, 
malaria is considered in the differential diagnosis of any fever and asymptomatic 
parasiteamia in endemic areas, but the discovery of parasites in the blood film confirms 
clinical suspicion of malaria (Payne et al 1988). 
More recent diagnostic methods include the use of Rapid Diagnostic Tests (RDTs) which 
are based on antigen derived from malaria parasites in lysed blood, using immuno 
chromatographic methods (Singh et al, 1997).  There are other methods, but they are not 
currently used for diagnostic purposes. They include molecular biological detection tests 
such as Polymerase Chain Reaction (PCR) or Transcript Amplification System (TAS), 
probe Amplification Ring Q-beta replicase and Signal Amplification using enzyme linked 
probes (Craig et al, 1997).  
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2.2: Burden of Malaria in Nigeria 
The WHO (2007) estimates that malaria causes a loss of about 1.3% annual economic 
growth in countries with intense transmission such as Nigeria. It is responsible for 30% 
of all childhood deaths, 11% of maternal deaths and 50% of all out-patient attendances 
(PAN, 1994). It is the most common cause of absenteeism amongst workers and school 
children, thereby impacting negatively on production and development (Asagba et al, 
1991). A study by the federal Ministry of Health in collaboration with the WHO reveals 
that the burden of malaria may be in excess of 14% of Gross Domestic Product and 98% 
of treatment cost is borne by citizens (FMOH, 2004). Apart from the high morbidity 
associated with the acute symptoms, the disease is also associated with low birth weight, 
anaemia, prenatal and maternal mortality (Janssens & Wery, 1987). 
 
2.3: Malaria Treatment and the Problems of Drug Resistance 
Chloroquine was introduced to treat malaria in the 1950s; it was fast, effective and cheap.  
However, widespread and uncontrolled use of chloroquine has contributed to the 
emergence and spread of resistance to the drug. Sulfadoxine-pyrimethamine (SP) was 
introduced for use in Asia (Thailand) in the early 1970’s and was only introduced in 
Africa in the early 1990’s, but resistance developed to SP in a short time. The 
development of drug resistance is the ability of the malaria parasite to survive in the 
presence of the minimum inhibitory concentration of a drug (WHO, 2000). The 
significant consequences of drug resistance are increased morbidity and mortality, as well 
as higher drug costs and an increased burden of the disease. A study conducted in 
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Senegal reported a strong link between the emergence of chloroquine resistance and an 
increase in malaria mortality between 1984 and 1995 (MSF, 2003). 
 
Anti-malarial drug resistance is increasing worldwide (WHO, 2006). In many African 
countries, including Nigeria, resistance to chloroquine and SP is very high and has 
rendered these drugs almost useless in the treatment of malaria. Strains of P. falciparum 
resistant to chloroquine were reported in the mid 1950’s in Colombia and Thailand 
(Bloland, 1999), the early 1970’s in Tanzania (Onori, Beales and Gilles, 1982) and high 
resistance to SP has also been reported in South East Asia and East Africa (Reacher et al, 
1981). The first case of chloroquine-resistant P. falciparum was recorded in Nigeria as 
early as 1987 (FMOH, 1990). The National Malaria Therapy Surveillance Network 
conducted in vivo studies from 1987 to 1988 on chloroquine and SP, using WHO 
standard protocols; the results indicated a high resistance of over 25% in the South-East 
and South-South geographical zones and between 10-25% in the North-Eastern and 
North-Central zones of the country for both chloroquine and SP (FMOH, 1989).  
 
Study reports seem to indicate that the problem of resistance to chloroquine and SP has 
been increasing steadily (Ezedinachi, 1996), with resistance levels of 27.3% and 60.5% 
recorded for SP and chloroquine respectively in parts of the Nigeria during the mid-  
1990’s (Falade, et al 1997). Another study was conducted to determine chloroquine 
sensitivity in the South-South area of Nigeria, in children aged 6 to 60 months, with 
parasitologically proven P. falciparum, using the WHO 14-day protocol for in vivo 
studies. A 65.2% treatment failure was reported, which is similar to, but slightly higher 
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than Falade’s 1997 results (Anita-Obong, et al, 1998). These figures are also higher than 
what is reported from Medicines San Frontiers projects which recorded 40% resistance 
for both SP and chloroquine in studies conducted in the Niger Delta region (South-South) 
of Nigeria (MSF, 2003). Resistance has also been reported to other anti-malarials such as 
mefloquine, halofantrine and quinine in places such as East Central Africa, South East 
Asia, Southern Africa, South America and many other parts of Africa, where they are 
widely used (WHO, 2000). 
 
More recently, in 2002, Drug Therapeutic Efficacy Tests (DTET) were conducted on 
chloroquine and SP in Nigeria and the results indicated that chloroquine and SP were no 
longer suitable for national first-line use. The results showed an efficacy of between 3.7% 
and 50.8% for chloroquine and 14.9% to 64.8% for SP (FMOH, 2005a). WHO guidelines 
recommend that treatment failure rates should be less than 5%, rates higher that 10% 
indicates that a change of treatment protocol should be established (WHO, 2000).  In 
areas where there is resistance to monotherapy, such as chloroquine and sufadoxine-
pyrimethamine, the World Health organization recommends artemisinin-based 
combination therapy as first line treatment for all patients with falciparum malaria 
(WHO, 2006). This justified the need to move from monotherapy to the more effective 
artemisinin-based combination therapy (ACT). As a result, further efficacy trials were 
conducted in 2004 by the Federal Minisitry of Health (FMOH) on two artemisinin-based 
combination therapies, namely, artemether-lumenfantrine and artesunate-amodiaquine, 
with 100% and 98% Adequate clinical parasitological Response Rate (ACPR)  
respectively, in the six geographical zones of the country. They were thus suitable for use 
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in the treatment of uncomplicated malaria (FMOH, 2005a). Nigeria therefore changed its 
anti-malarial treatment policy to the artemisinin-based combination therapy in 2005, 
although widespread implementation did not commence until 2006.  
 
2.4: Artemisinin-based combination therapy  
In order to prevent the emergence of resistance, malaria will no longer be treated with a 
single drug, but two or more drugs in combination. This combination approach has 
already been used successfully in the management of HIV/AIDS, cancer, tuberculosis 
and leprosy. In the treatment of malaria artemisinins are combined with an antimalarial 
which is long acting and has a different biochemical target in the parasite. 
 
Artemisinins (Qinghaosu) are the active constituents of the Chinese herb Artemisia annua 
and have been used by the Chinese in the treatment of malaria for over 400 years.  The 
artemisinins, which are highly effective against multi-drug resistant malaria, undergo a 
reduction reaction to dihydro-artemisinin and also inhibit the development of 
gametocytes and therefore a potential reduction in the transmission of mutants which are 
responsible for the development of resistance.  Artemisinins have a short half-life and so 
do not remain in the body for long. They are therefore combined with a blood 
schizonticidal drug, such as lumenfantrine, amodiaquine or mefloquine.  This other 
antimalarial lasts longer in the body and “mops up” the parasites that may have escaped 
from the action of the artemisinin. The combination works synergistically to treat malaria 
and to reduce the emergence of resistance.  
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Artemisinin-based combination therapy produces rapid clinical and parasitological cures, 
is well tolerated and reduces gametocyte carriage rate (Bloland, 2001). ACTs have been 
formulated in a fixed combination where components are co-formulated in the same 
tablet or capsule, for example artemether-lumenfantrine (Coartem) or the separate 
components are co-blistered, for example artesunate-amodiaquine (Arsucam, Larimal and 
Dart). The first-line ACT is Coartem® – artemether/lumenfratrine and second line is 
artesunate/amodiaquine (FMOH, 2005a). In order to ensure broad access to ACTs, the 
first line and second line ACTs were switched from being a prescription-only medicines 
(POM) to over-the-counter (OTC) status in late 2006 by the Medicine Regulation Agency 
(NAFDAC), so that PMVs can legally stock and sell them. It is important to note also 
that all other ACTs remain prescription-only medicines and other non ACT antimalarials 
are POMs. Nigeria is the only country to have switched two ACTs to full OTC status; 
Ugandan has a partial re-classification, where the first line ACT has OTC status in two of 
the 86 provinces in the country (ACTwatch, 2008) 
 
2.5: National Anti-malaria Treatment Policy 
The National Anti-malaria Treatment Policy was launched in May 2005. The policy 
presents an overview of the malaria situation, treatment and anti-malarial drugs in 
Nigeria. In addition to chemoprophylaxis in the control of malaria, the policy also 
outlines the health promotion activities for the control of malaria.  The strategy for 
implementing the policy is the same as that of the Roll Back Malaria (RBM) initiative.  
The strategy has four key elements. 
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(i) Patients with malaria should have access to appropriate and adequate 
treatment within 24hours of the onset of symptoms. 
(ii) Pregnant women during their 1st and 2nd pregnancies should receive effective 
antimalarial prophylaxis and treatment. 
(iii) Insecticide treated bed-nets and other materials are to be available and 
accessible to vulnerable groups, namely children and pregnant women   
(iv) Malaria epidemics should be recognized and containment steps initiated 
within one week of their onset. (FMOH, 2005a). 
 
The policy emphasizes prompt and effective treatment of malaria, especially in children, 
within twenty-four hours of onset of illness. According to the policy the first drug of 
choice for the treatment of uncomplicated malaria is the ACT, artemether-lumenfantrine 
(Coartem®). When this is not available artesunate-amodiaquine, artesunate-mefloquine 
or dihydro-artemisinin + piperaquine+trimetoprim may be administered.  The national 
anti-malarial treatment guidelines states explicitly that “Monotherapy with dihydro-
artemisinin, other artemisinin derivatives and other antimalarial medicines are not 
recommended. Treatment must be used in combination with another effective 
antimalarial drug” (FMOH, 2005b). 
 
Artemisinin-based combination therapies (ACTs) have been found to be safe and well 
tolerated in children and are recommended in the treatment of uncomplicated malaria.  
There are different dosage regimens for the different ACTs. For example artemether-
lumenfantrine (Coartem) has four different dosage regimen for different weight/age 
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categories; 6-14kg (6mths-3years), 15-24kg (4-8years), 25-34kg (9-14years), >35kg 
(>14years). In the case of dihydroartemisinin-piperaquine, it’s even more complicated 
because the available brands come in with 8 or 10 tablets in a pack. This obviously 
presents a problem to dispense the correct dose or give the correct dosage instructions for 
the different age group. The forgoing underscores the concerns that these varying dosage 
regimens for the different ages may contribute to the problem of inappropriate 
prescribing or inaccurate dosages, causing treatment failures and drug resistance.  
 
Severe malaria is a medical emergency and the policy therefore recommends parenteral 
treatment (intramuscular or intravenous infusion), with quinine as the first drug of choice 
in the treatment of severe cases of malaria; parenteral artemisinin derivatives may also be 
used as alternatives. However an ACT must be administered as soon as the patient can 
tolerate oral medication to complete the antimalarial course. In all malaria cases whether 
uncomplicated or severe, the full course of treatment should be administered (FMOH, 
2005a). 
 
The policy is silent on the status of chloroquine, the first line antimalarial drug before the 
introduction of artemisinin-based combination therapy; however, in implementing the 
policy the National Agency for Food and Drugs Administration and Control (NAFDAC) 
stopped the registration of chloroquine and only permits renewal of old licenses. The 
Agency has also changed the status of chloroquine to a prescription-only medicine 
(POM), as an outright ban caused a huge outcry, and it is now reserved for other purposes 
such as in the treatment of amoebiasis.  
 
 
 
 
 12
2.6: Intermittent Preventive Treatment 
The prevention of malaria in pregnancy is of great importance, as malaria is a major 
cause of maternal morbidity and adverse birth outcomes. In areas with high malaria 
transmission rates, the WHO currently recommends intermittent preventive treatment 
(IPT), which consists in the administration of a single curative dose of an efficacious 
antimalarial drug at least twice during pregnancy. This is administered under supervision 
during antenatal care visits (Briand, et al, 2007). Sulfadoxine-Pyrimethamine (SP) has 
proven to be effective and is currently used for intermittent preventive treatment during 
pregnancy in Nigeria. In view of the foregoing, SP is no longer recommended for the 
treatment of uncomplicated malaria in Nigeria, in order to safeguard the therapeutic 
lifespan (FMOH, 2005b). In areas of multi-drug resistance the WHO recommends ACT 
and are considered safe in the 2nd and 3rd trimester of pregnancy, though the study by 
McGready et al indicates  that a higher close may be necessary because of observed low 
drug levels (McGready, et al, 2007). 
 
2.7: Home Management of Malaria 
In order to address the growing problem of malaria, Roll Back Malaria (RBM) a global 
partnership was founded in 1998 by the United Nations.  The overall goal of RBM is to 
cut African malaria deaths by 50% by 2010, and the specific targets are as follows:  
• to ensure that 80% of those suffering from malaria have prompt access to correct, 
affordable and appropriate treatment. 
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• to ensure that at least 80% of those affected by malaria benefit from suitable 
protective measures, such as insecticide treated nets and 
• to ensure that 100% of all pregnant women at risk for malaria receive 
chemoprophylaxis (WHO, 2005a). 
 
One of the major strategies to achieve the RBM goals is prompt access to effective 
antimalarial treatment; this means treatment should be available as close to the home as 
possible so that it is given within 24 hours of the onset of symptoms.  Home management 
of malaria has been shown to be effective in ensuring prompt access to appropriate 
treatment in Africa, especially in the remote areas (WHO, 2004).  A number of studies 
have provided evidence that home management reduces the progression of malaria to the 
severe form by more than 50%, and under-five overall mortality by 40% (Kidane & 
Morrow, 2000, Sirima , 2003). 
 
A number of constraints have been identified in meeting the first RBM target including 
poverty, distance of home from health facilities, hours of health service operations, cost 
consideration, drug stock outs and the unfriendly nature of health workers (Jowett & 
Miller, 2000; McCombie, 1996; Williams & Jones, 2004).  These factors have 
encouraged mothers/caregivers to source drugs from the informal or private sector, with 
sometimes inappropriate or poor quality drugs, contributing to drug resistance, which 
could in this era of ACT eventually undermine the therapeutic life of these drugs.  
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2.8: Medicine Sellers and Pharmacists 
Medicine sellers first started to engage in business in Nigeria in about 1889, when 
European medical officers began training natives in the coastal cities where they carried 
out their business. The colonial government in Nigeria did not make any concrete effort 
to train professionals to handle medicines until 1927, when a medical Board of 
Examiners was formed and the School of Pharmacy at Yaba, Lagos, was formally set up 
to train dispensers.  The first set of pharmacists graduated from the University in the late 
1960’s.  This means that non-pharmacists had been handling drugs in Nigeria for over 50 
years before the first set of pharmacists graduated (PCN, 2003). This long-standing 
existence of medicine sellers in Nigeria underscores their role in medicine supply and 
highlights their relevance and importance in this study. 
 
2.9: Patent Medicine Vendors 
Commercial retailers of drugs in the informal private sector are known by a variety of 
names including medicine sellers, drug sellers, chemical sellers and patent medicine 
vendors (PMVs).  They operate in general shops, market stalls and as itinerant hawkers 
(Goodman et al, 2007).  This study will focus on patent medicine vendors; these are non-
pharmacists who are licensed by the Pharmacist Council of Nigeria to stock and sell 
simple medicinal remedies.  The pharmacy law of Nigeria stipulates that PMVs should 
sell only pre-packaged patent medicines, without splitting the pack (Egboh, 2004). Patent 
medicines are over the counter drugs (OTC) or non-prescription medicines commonly 
used as household medicaments.  They are oral or external preparations in unit pack sizes 
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used only for a brief medical intervention. These outlets are not permitted to stock 
prescription-only medicines (POM), only over-the-counter (OTC) products which include 
cough syrups, pain killers and some anti-malarials. (PCN, 2003).  
 
PMVs are required to be licensed by the state Pharmacist Council, who issues the Patent 
and Proprietary Medicine Vendor’s license (PPMVL). The more established and 
experienced patent medicine vendors (PMV) usually have one or two shop assistants to 
assist with sales at the shop.  The basic requirement by law to be licensed as a patent 
medicine vendor is the ability to read and write in English, a minimum of primary school 
education and good character. Most PMVs do not have a technical or professional 
background in pharmacy or medicine, however, the Pharmacist Council usually conducts 
orientation training for new patent medicine vendors. This training serves to educate the 
vendor on his role in the healthcare delivery system, and the ethics and guidelines 
governing the selling of patent medicines in Nigeria. Many PMVs have attended several 
one or two-day seminars organized by stakeholders such as the National Agency for Food 
and Drug Administration and Control (NAFDAC), National Drug Law Enforcement 
Agency and non-governmental organizations and drug manufacturing companies. 
Evidence exists that there is a strong willingness among PMVs to attend training and they 
are even willing to pay for course (PATH, 2006, unpublished data). 
 
In addition to the Pharmacist Council of Nigeria (PCN) licensure, medicine vendors often 
register as members of a district, state or national trade association. Although these trade 
associations have no legal status, they serve as a platform for prestige, social control and 
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as a pressure group in dealing with the legal authorities (Breiger, et al, 2004). In Nigeria 
the national trade association for PMVs is known as the Nigerian National Association of 
Patent & Propriety Medicine Dealers (NAPMED) and has regional, state and local area 
offices. The unlicensed vendors form a sizeable portion of vendors in any state, there are 
no official figures in this regard. There are complaints from the licensed vendors that the 
unlicensed vendors are the ones responsible for the unwholesome practices observed in 
the trade, such as selling prohibited products, breaking a pack to sell or engaging in other 
practices contrary to the tenets of the patent medicine vendor regulations.(PATH, 2006 
unpublished). 
 
2.10: Regulation of Patent Medicine Vendors 
The Pharmacist Council of Nigeria (PCN) is the regulatory authority in charge of 
pharmacy practice and patent medicine vendor operations. The PCN is responsible for 
registration, licensing and monitoring of patent medicine vendors. Unfortunately, the 
oversight activities of monitoring are currently weak due to a six year legal battle 
between the PCN and the patent medicine vendors. 
 
In 1990, the local government councils were authorized to issue the patent medicine 
licenses by the then Minister of Health. This, however led to a lot of abuse as the local 
government officials, who were political office holders without medical or scientific 
training, used the privilege to serve their own purposes by issuing the licenses without 
adhering to the guidelines issued by the Pharmacist Council of Nigeria. In 1992 the 
authority to issue licenses was reverted to the PCN, but this was challenged with a court 
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injunction which stopped the issuing of licenses completely, and only after a long battle 
in court did the licensing authority finally revert to the PCN in April 2003. This 
administrative unrest resulted in a bottleneck in the issuing of licenses and was a major 
hindrance to regulatory activities which is now slowly being addressed (PCN, 2004).  
 
The National Agency for Food, Drug Administration and Control (NAFDAC) is the 
agency tasked with the mandate to control the sale, export, import, distribution, 
manufacture and use of medicines in Nigeria. Their activities include visits to shops 
where drugs are sold, including patent medicine shops. These inspection visits are 
conducted to ensure that only products duly registered with NAFDAC are being sold as 
stipulated by law. However, so far regulation has been poor and visits are irregular 
(NAFDAC, 2004). This has resulted in vendors stocking illegal products such as 
prescription only products unregistered by the Agency or selling fake and expired drugs. 
This problem of irregular visits by regulatory authority is not peculiar to Nigeria as 
literature evidence indicates. (Goodman, et al, 2007). 
 
2.11: Patent Medicine Vendors Practices  
The practices of patent medicine vendors are of concern as they are a widely patronized 
source of drugs for the home management of fever/malarial illnesses, and anti-malarials 
rank high among drugs sold by medicine vendors in Nigeria (Iweze, 1987). Study reports 
of home treatment have indicated that drugs bought from vendors and used in the home 
management of malaria are often inappropriate and in the wrong dosages (Goodman, et 
al, 2007). In the case of childhood malaria this represents a major problem since many 
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deaths occur within 48 hours of the onset of illness if not treated effectively (Greenwood, 
et al, 1987). 
 
A review of studies of medicine sellers’ practices across Africa has shown that they have 
frequently abused the privilege conferred on them by sale of expired drugs, and other 
suspect practices.  They often stock prescription only medicines (POM) such as 
antibiotics, antihypertensive and tranquillisers (Fussin,1988; Oshiname & Breiger, 1992). 
They handle drugs inappropriately storing them in conditions of moisture, light and 
excessive heat which could damage their potency (Battersby, et al, 2003). It has also been 
documented that the drugs sold may be inappropriate for the complaint, such as selling 
aspirin to treat childhood malaria (Abiola, et al, 1983; Nshakira, et al, 2002) and the 
practice polypharmacy where additional unnecessary drugs such as antibiotics, aspirin 
and multi-vitamins are dispensed (Okoro & Jones, 1995). 
 
 
The quality of the drugs presented for sale has also been questioned. There has been 
evidence of dispensing drugs of substandard quality as a result of poor manufacture and 
storage (Basco, 2004).  In Nigeria, like in many countries around the world especially the 
developing countries, the problem of counterfeit and fake drugs is huge. However there is 
evidence that suggests improvements, this is attributed to the frontal attack launched by 
the medicine regulatory Agency (NAFDAC).  In 2001, the counterfeit and fake drugs in 
the system were estimated to be between 41% and 70%, In 2004, the level was estimated 
at 35% and 15% to 30% (Science in Africa, 2007).  Studies conducted in sub-Saharan 
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Africa Anti-malarial drugs collected from medicine sellers in urban and rural areas were 
found to have insufficient active, no active, or the wrong active ingredients. The 
packaging, labeling and dosing information of the products were also found to be 
inadequate and in conflict with national treatment guidelines (Goodman, et al, 2007).  
 
Some of these practices have been linked to the expectation and demand of the consumer 
as it has been reported that in most situations, the medicine vendor simply sells what the 
customer requests for fear of losing business (Akuse, et al, 2004; Breiger et al, 2004). It 
has also been argued unconvincingly that selling an inappropriate dose may be as a result 
of the inability of the customer to buy the complete dose (Iweze, 1987). There are reports 
which suggest that a lack of knowledge of the appropriate dose may be responsible for 
selling wrong or inappropriate dosages. For example, in a study by Oshiname & Breiger 
(1992), it was reported that only 2% of the vendors knew the correct dose of chloroquine 
for a 3-year old child.  Frequently, neither the medicine vendor nor the consumer knows 
the correct dosage or length of treatment (Gomes, Wayling & Pang, 1998).   
 
The sources of drugs sold by medicine vendors have been widely documented. Study 
reports indicate that they obtain their drugs from large retailers, wholesalers, wholesale 
pharmacies, and from mobile distributors, if the vendor is located in remote and hard to 
reach rural areas (Adiukwu, 1996; Goodman et al, 2007).  The main source of medical 
information is sales representative from pharmaceutical companies and pharmacies, as 
government activities usually target the formal health facilities (Goodman, 2004; Ongore 
& Nyabola, 1996).  
 
 
 
 
 20
 
A number of concerns have been raised with regard to medicine vendor practices and the 
introduction of artemisinin-based combination therapy. These include the high price and 
susceptibility to degradation by sunlight and moisture of these drugs. Improper storage in 
a tropical country such as Nigeria is of concern, as they may become ineffective due to 
degradation, if not stored away from sunlight, heat or moisture. Another major concern is 
the availability in the market of oral artesunate monotherapy, which though effective and 
cheaper than ACTs is not recommended in the policy, because it is monotherapy and 
continued use will lead to the rapid emergence of resistance to the ACTs.   
 
Moreover, artesunate has been on sale and commonly used in malaria treatment before 
the introduction of the ACTs. Cost considerations have been cited as a motivation for the 
continued use of artesunate and other monotherapy anti-malarials. Artesunate costs on the 
average N393 (US $ 3.14) whereas ACTs cost about N504 ($ 4.03) for a treatment course 
in the private sector. This is considerably more expensive than the older antimalarials on 
the market such as chloroquine and sulfadoxine-pyrimethamine (SP) monotherapy which 
cost about N83 (US$ 0.66) and N91 (US$ 0.73) respectively (Oladepo, et al, 2007). 
 
Presently some ACTs do not come as fixed dose but as two separate components tablet 
co-blistered. There are concerns that PMVs, due to a lack of knowledge or other reasons, 
may break the pack into its components tablets and sell individual components, which 
may lead to the rapid emergence of resistance and increase the malaria burden. 
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2.12: Patent Medicine Vendor Interventions 
Extensive literature exists documenting the utilization, existing role, strengths and 
shortcomings of medicine vendors, and the recommendations for legal or educational 
interventions (Jimmy, Achelonu & Orji, 2000; Okeke et al, 2006; Oshiname & Breiger, 
1992). However, intervention studies are scarce and the explanation given for this is that 
in many countries interventions targeting unqualified drug sellers, such as patent 
medicine vendors meet with a certain amount of resistance from both professional bodies 
and regulatory organizations.  In addition, patient demands, vendors focus on profit 
making, herbal and alternative therapies, and the documented difficulty of achieving 
rational prescribing in the commercial private sector has contributed to this dearth of 
interventions (WHO, 1998).  
 
A review of medicine vendor interventions in sub-Saharan Africa reported that they were 
implemented in widely varying settings; rural, urban and peri-urban (Goodman et al; 
Greer et al, 2004; 2007). The number of vendors in the different interventions ranged 
from less than 10 to 500, with a median of 50. The major method of collecting 
information was using structured questionnaires administered to sales staff, sometimes 
supplemented by in-depth interviews, undercover care-seekers, exit interviews, direct 
observation and household surveys.  Studies documented were mainly research trials or 
donor sponsored projects.  The review indicated that there were two main categories of 
interventions involving the vendors; in some cases the vendors were the main focus of the 
intervention, such as where vendors in a rural community in Nigeria were trained 
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(Oshiname & Breiger, 1992). In other cases the vendors were part of a larger community 
health intervention as in the Healthy Happy Homes initiative in Ghana (He Ha Ho, 2003).  
 
The main types of interventions recorded were: capacity building to improve knowledge 
and communication skills; creating an enabling environment through policy, demand 
generation using the media; and drugs quality assurance through franchising, monitoring 
and supervision. There appeared to be no distinct pattern in terms of the type of 
intervention and results obtained and it has been argued that a suitable model of 
intervention has not been found and that interventions are usually case specific based on 
prevailing conditions and desired results. (Greer, et al, 2004). 
 
A number of interventions reported training on correct drug use, choice and dosages as a 
common element, through workshops and sometimes supplemented with in-shop or peer 
education training (Kaona & Tuba, 2003; Ross-Degnan, et al, 1996).  In general, the 
interventions reported improvements in vendor performance or caregivers being 
dispensed an age appropriate dose of a recommended drug. It was also shown that 
medicine vendors who received training were also more likely to stock approved anti-
malarials, such as color-coded, dose and age-specific prepackaged anti-malaria drugs. 
Nevertheless, it has also been suggested that assessing the success of the intervention 
should not stop at just improvement in knowledge or evidence of giving the correct dose, 
but should be determined in terms of overall improvement of a reduction in child or 
maternal mortality and other health indicators (Oshiname & Breiger, 1992).  
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The foregoing provides an overview of information regarding documented practices and 
knowledge of vendors in the sale of drugs. The next chapter will give information on the 
aim and objectives of this study. 
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CHAPTER 3: AIM AND OBJECTIVES 
3.1: Aim 
The aim of the study was to describe the knowledge and self-reported practices of patent 
medicine vendors (PMVs) in the use of antimalarials, particularly Artemisinin-based 
Combination Therapy, in the treatment of malaria. 
 
3.2: Objectives 
The objectives of the study were; 
(1) To determine the proportion of patent medicine vendors (PMVs) with the 
correct knowledge of the signs and symptoms of malaria. 
(2) To determine the knowledge of patent medicine vendors (PMVs) in the use of 
ACTs.  
(3) To describe the self-reported practices of patent medicine vendors (PMVs) in 
the use of antimalarials especially ACTs in the treatment of malaria. 
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 CHAPTER 4: METHODOLOGY 
4.1: Study Design 
A cross-sectional, descriptive study design was chosen because it has been shown to be 
objective, credible and of scientific rigor to quantify and describe knowledge and 
practices (Blanche and Durrheim, 2006).  
  
4.2: Study Population and Sample  
The study population was all licensed patent medicine vendors in Mushin, Lagos. 
Unlicensed premises were excluded, because, they are not recognized by the government. 
The list of registered premises was obtained from the Pharmacy Council of Nigeria. 
Fifty-seven shops were identified and 52 of them participated in the study. In each shop, 
the owner of the shop and one shop assistant were recruited for interviews. The shop 
assistants were included in the sample because in reality they attend to the clients.  If 
there was more than one shop assistant on duty, then the assistant to be interviewed was 
determined by flipping a coin.  
 
4.3: Data Collection 
A structured questionnaire with closed and open ended questions was used to collect the 
data. Information collected included demographic data on the vendors, their knowledge 
of malaria, the ACT policy, ACTs, and self-reported practices regarding the use of ACTs. 
Before data collection started, the researcher met with the chairperson of the National 
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Association of Patent Medicine Dealers (NAPMED), Mushin Branch, to seek support and 
approval to carry out the study. The participant information sheet (Appendix 2) and 
informed consent form (Appendix 3) were presented and assurances given by the 
researcher of the confidentiality of the information and written approval was granted. 
Data collection commenced after the written approval was received. 
 
 The interviews were conducted in English, as all participants can speak English which is 
the major language of business in Lagos. After explaining the reason for the study, 
consent was sought and the informed consent form presented to them for their signature. 
The interview was conducted after signing the informed consent form. As regards the 
question regarding the appropriateness of ACTs during pregnancy, it was assumed that 
once the PMV was aware that a patient was pregnant, the patient was considered to be 
either in the second or third trimester of pregnancy. A copy of the questionnaire is 
attached in Appendix 1.   
 
Four intern pharmacists were recruited and trained by the researcher to administer the 
questionnaire to patent medicine vendors and they carried out the data collection. The 
questionnaire was pre-tested on seven patent medicine vendors at the Lawanson area of 
Lagos, which is similar to the study site in terms of socio-economic status and socio-
economic activities of the population. Some adjustments were made to the questionnaire 
for clarity, such as the serial number was changed to be continuous throughout the 
different sections of the data collection tool, instead of starting a new serial number in 
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each section. Responses of the interviews were recorded in duplicate, to check data 
quality.  
 
4.4: Data Management and Analysis 
In order to ensure that there was no missing data, the data collectors checked the 
questionnaires for completeness before leaving the site. In addition, the questionnaires were 
cross checked by the researcher and then entered into Excel and subsequently exported to Epi 
Info (3.2) by a data clerk. There were two teams of two persons per team. In each team, both 
persons recorded the responses; this means there was double entry of data to ensure accuracy. 
 
Descriptive statistics were used to compute mainly; frequencies, proportions and means 
(or medians where distribution is not normal) for all important variables in the data set. 
The demographic variables were cross-tabulated with other variables such as training, 
educational qualification and length of employment as a medicine vendor and other 
knowledge and practice variables, to see if there were associations. These variables were 
chosen because some knowledge, attitude and practice (KAP) studies have reported 
associations between demographic variables, educational qualification and other practice 
and knowledge variables. These associations were tested using the chi-squared test, with 
p-values of < 0.05 considered statistically significant and when the value of the variable 
was less than 5 the Fischer’s exact test was applied. 
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4.5: Validity and Reliability 
Measurement bias was minimized by first of all using a pre-tested questionnaire. The 
questionnaire was designed to be simple, short and appropriately formatted to reduce 
errors of data collection and entry into the database. Furthermore, the data collectors were 
adequately trained and the tool piloted so that requisite skills were acquired before 
implementing the survey. Since no gold standard or other means of validation of findings 
exist, it was recognized that the study may be subject to information bias because since 
these practices are self-reported, the respondents may report what they feel they should 
be doing not what they do in reality. Selection bias was ruled out by having an inclusive 
sample. Five eligible vendors chose not to participate, this was not expected to create 
selection bias, given that it was an inclusive sample, and this was not likely to have a 
great effect on the findings of the study.  
 
4.6: Generalisability 
It will not be possible to generalize the results of this study to the whole of Lagos State as 
only one community was used. The study results may be more relevant in settings similar 
to Mushin; urban area, with low socio-economic population. . It is also anticipated that 
the study results will have relevance more broadly, specifically in generating hypotheses 
for further testing. 
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4.7: Limitations 
 A limitation of this study was that unlicensed medicine vendors were excluded. This is a 
limitation because unlicensed vendors may have different practices to those who are 
licensed and thus the study only reports on knowledge and self-reported practices of one 
group of PMVs.  
 A further limitation was the use of self-report measures, which has been documented to 
produce information bias.  This study aimed to provide insight to inform further 
investigations and interventions, and, as is the case with most cross-sectional studies, the 
associations in this study cannot be assumed to be causal, as establishing temporality is 
problematic in this type of study design. 
 
4.8: Ethical Considerations 
The proposal was approved by the Ethics Committee of the University of the Western 
Cape. The point of entry to the medicine vendors was through the chairperson of the 
Mushin Medicine Dealers Association (MMDA) and written consent approval was 
obtained prior to commencement of the survey. Participants were given the participant 
information sheet and the informed consent form (Appendix 2 and 3).  
 
It was further explained that participation was voluntary; no harmful procedures were 
involved in the study and they were free to withdraw from the process at any stage of the 
project, even after initial consent is given. They were also assured of the confidentiality 
of the information they provided as the results will be presented in an aggregated form 
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and cannot be traced to any individual person or premises. Information from this study 
will be made available to the MMDA and the RBM case management sub-committee. 
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CHAPTER 5: RESULTS AND DISCUSSION 
5.1: RESULTS 
This section presents the results of knowledge and self-reported practices of patent 
medicine vendors in a poor urban community in Lagos in the use of antimalarials, 
especially ACTs, in the treatment of malaria. 
 
5.1.1: Characteristics of participants 
A total of 105 vendors were interviewed out of a sample size of 114; indicating a 92% 
response rate. The study sample consisted of 82 (78%) males and females 23 (22%). The 
ages ranged from 15 to 54 years with a mean (SD) of 31.5 (10.40) years. More than half 
of the participants were between the ages of 21 and 30 years. Most respondents were 
educated; over two-thirds had secondary school education while only four did not have 
any formal education. Experience as a medicine vendor varied widely; about 38% have 
worked 3 years or less, whilst about a quarter have worked for over 10 years (Table 1). 
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Table 1: Demographic characteristics of patent medicine vendors in Mushin 
(N=105)   
Characteristic Frequency Percentage (%) Mean + SD 
Sex    
Female 23 22  
Male 82 78  
Age (years)   31.50+ 10.40 
15-20 11 10  
21-30 59 56  
31-40 18 17  
41-50 7 7  
51 and above 10 10  
Education    
No formal education 4 4  
Primary School 33 31  
Secondary School  62 59  
Tertiary  6 6  
Experience as a PMV   8.09 + 8.69 
 < 3 years 40 38  
4 –10 years 40 38  
 Above 10 years 25 24  
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5.1.2: Training 
The study results indicated that 75% of the vendors have received training as a patent 
medicine vendor. This orientation training is facilitated by the Pharmacist Council of 
Nigeria (PCN), 44% of respondents have had training in malaria and malaria related 
topics in the last three years. However, only 21% have had training in the ACT policy 
since its inception in 2005. 
 
5.1.3: Knowledge of signs and symptoms of uncomplicated and severe 
malaria 
Hotness of body/high temperature, headache and loss of appetite were the most 
frequently reported signs and symptoms of malaria reported by 94%, 86% and 75% of the 
medicine vendors, respectively. This was followed closely by joint pains, dark colored 
urine and vomiting reported by 79%, 78% and 61% respectively (Table 2).  
 
Table 2:  Signs and symptoms of malaria reported by patent medicine vendors in 
Mushin (N=105) 
Signs and symptoms of malaria Frequency (n) Percentage (%) 
Hotness of body/high temperature  99 94 
Dark colored urine  78 74 
Joint pains  79 75 
Headaches 90 86 
Loss of appetite 82 78 
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Vomiting  61 58 
Weakness/dizziness 46 44 
Cold/rigors 28 27 
 
Knowledge of symptoms of severe malaria was poor. Whilst the vendors mentioned 
symptoms of uncomplicated malaria such as high temperature (fever), headaches and 
joint pains and only 11% mentioned convulsions, which is the most critical clinical 
symptom of severe malaria for immediate referral to a health facility. However, reported 
knowledge of conditions for referral was high as 88% and 74% mentioned that patients 
would be referred if there is no improvement after completing the malaria treatment and 
severe malaria, respectively.  
 
5.1.4: Knowledge ACT Anti-malaria Policy and ACTs  
Awareness of the national anti-malaria ACT policy was high, 96% (101) mentioned that 
they had heard about it. Over 80% of the respondents mentioned that they heard about the 
policy from a representative of the drug manufacturers or distributors, while 15% and 4% 
obtained the information from the Mushin Medicine Dealers Association (MMDA) and 
government sources, respectively (Figure 1).  
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Figure 1: Source of information on the ACT policy by patent medicine vendors in 
Mushin, Lagos (N=101) 
 
The vendors in the study demonstrated adequate understanding of the reason for the 
policy change; 62% answered correctly that the reason is that ACTs are more potent than 
chloroquine in malaria treatment. Knowledge of the recommended use of sulfadoxine-
pyrimethamine (SP) according to the policy was average: 56% (57) answered correctly 
that it is for intermittent preventive treatment (IPT) of malaria in pregnant women, while 
41% erroneously considered SP as second line drugs to chloroquine.   
A large number of respondents, over 80%, believed that chloroquine is still in useful in 
the treatment of malaria, while 57% and 19% considered ACTs safe in pregnant women 
and breastfeeding mothers, respectively. 
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Respondents were asked to give their opinions on the effectiveness of ACTs compared to 
chloroquine and fansidar (sufadoxine-pyrimethamine). These were first line and second 
line antimalarials in the previous malaria policy; 29% and 51% correctly answered that 
ACTs are more effective than chloroquine and fansider respectively (Table 3).  
 
Table 3: Patent medicine vendors’ perceptions of the effectiveness of ACTs 
compared with chloroquine (CQ) & fansider (SP) (N = 101). 
  
Variable Frequency (n) Percentage % 
ACTs are more effective than chloroquine 29 29 
ACTs have same effectiveness as chloroquine  70 70 
ACTs are less effective than chloroquine. 2 2 
ACTs are more effective than fansider 51 51 
ACTs have same effectiveness as fansider 48 48 
ACTs are less effective than fansider 2 2 
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Table 4: Knowledge of what constitutes an artemisinin-based combination therapy 
(ACT) anti-malarial by medicine vendors in Mushin (N=101). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Respondents were graded according to the responses provided when asked to mention 
two artemisinin-based combination therapy anti-malarials. Being able to mention two 
ACTs correctly was rated as good; fair, if one is mentioned correctly; and poor for no 
correct answer. All PMVs who mentioned two ACTs correctly also mentioned the first 
line ACT artemether-Lumenfantrine (Coartem) as one of the ACTs.  Interestingly 14% 
wrongly considered artesunte as an ACT. 
 
 Variable Rating Frequency Percent 
Mentioned 
two ACTs 
correctly 
 
good 
 
14 
 
13.9 
Mentioned 
one ACT 
correctly 
 
fair 
 
40 
 
39.6 
Unable to 
mention any 
ACT  
 
poor 
 
15 
 
14.9 
No response  32 31.7 
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5.1.5: Self-reported Practices: Stock Control and Usage of ACTs. 
The study results showed that 35% of the medicine vendors had started stocking ACTs 
from 2005. Acceptance of this anti-malarial seemed to be high as well as over 60% of the 
vendors have been stocking ACTs since 2007. The main sources of supply mentioned are 
distributors and manufacturers. They also demonstrated a good knowledge of the storage 
conditions for ACTs as 90% reported that sunlight affects these drugs and 85% stored 
them away from sunlight.  
Despite this seemingly high acceptance of ACTs, in practice 71% (72) and 55% (56) of 
the vendors currently sell chloroquine and sulfadoxine-pyrimethamine, respectively, to 
treat malaria. (Table 5). 
 
Table 5: Self-reported practices of the patent medicine vendors in the usage, stock 
and sale of ACTs (N=101) 
Variable Frequency (n) Percentage % 
Year started Selling ACTs: 
2005 
2006 
2007 
2008 
 
35 
32 
30 
4 
 
35 
32 
30 
4 
Source of ACT Stock: 
Other outlet/pharmacy shops 
Manufacturers  
 
3 
32 
 
3 
 32 
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Distributors 66 65 
Can share or break the pack of ACT to sell 41 
 
41 
Asks for age of user 
 
70 69 
Explains drug dosage  
 
41 41 
Provided dosage information 
Correct 
 
20 
 
49 
Incorrect  21 51 
 
Moreover, when told to rank the anti-malarial most frequently recommended, to their 
customers in the two months prior to the study, chloroquine, ACTs, and others (mainly 
artesunate monotherapy) were ranked as first choice antimalarial, by 58% , 17% and  8% 
respectively,  oral artesunate monotherapy was reported by 7%. (Figure 2) 
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.
 
Figure 2: Most frequently recommended anti-malarial by patent medicine vendors 
in Mushin two months prior to study (N=101). 
When asked to rank factors determining what anti-malaria drug was sold in the past 2 
months “what the customer requests” was ranked as the most important factor by 37% of 
respondents. This indicated that the vendor tended to sell what the customer wants 
regardless of whether it was appropriate (Figure 3). 
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Figure 3: Most important factors determining anti-malarial sold to customers 
(N=101). 
Other practice results showed that 40% would share or break the ACT pack to sell to 
customers and 70% would ask for the age of the user before selling. However, only 41% 
would explain the dose, out of which only about 50% gave the correct dosage of Coartem 
(aretemether-lumenfantrine), the first line ACT anti-malarial.   
 
Tables 6-9: Results of 2 by 2 analysis using different variables. The p-values in bold, are 
statistically significant suggesting an association between the variables. 
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Awareness of the ACT policy by the PMVs was very high (96%) but those with 
secondary/tertiary education were more likely to be aware of the policy and to have had 
training on the policy than those with primary or no formal education (with statistically 
significant p-values (Fischers’ exact test) of 0.0138 and 0.005 respectively. A greater 
percentage of those with secondary/tertiary education said that ACTs were unsuitable for 
use in pregnancy, however, they were less likely to ask the specific age of the user.  
(Table 6). 
Table 6: Comparison of medicine vendor educational qualification with knowledge 
of the ACT policy and self-reported practices in the use of ACTs. 
 
VARIABLE EDUCATIONAL 
QUALIFICATION DF P-value OR 95% CI 
 No formal/ 
Primary 
Secondary/
Tertiary 
    
Awareness of 
Policy 
  1 0.0138*   -  
Yes 33 (89%) 68 (100%)     
No 4 (11%) 0(0%)     
Knowledge of ACT 
suitability in 
pregnancy 
      
Suitable  25 (76%) 33 (49%) 1 0.017** 3.3144 1.3111  
   to 8.3784 
Not suitable 8 (24%) 35 (51%)     
Knowledge of ACT 
suitability in 
breastfeeding 
women 
      
Suitable  6 (18%) 14 (21%) 0.9853 1.000 0.2963    to 2.4793 
Not suitable 27 (82%) 54 (79%)   
 
Reason for change 
in policy 
     
Additional drug to 
CQ 
14 (42%) 24 (35%) 0.6349 0.517 0.5769 to 3.1633 
ACTs more potent 19 52%) 44 (65%)   
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Training on Policy      
Trained 2 (6%) 21 (31%) 0.005* 0.005 0.0316 to 0.6600 
Not trained 31 (94%) 47 (69%)   
Ask for specific age 
of user 
     
Yes  29 (88%) 41 (60%) 0.005* 0.005 1.5076 to 15.1201 
No  4 (12%) 27 (40%)   
CQ still used in 
malaria treatment 
     
Yes  31 (94%) 53 (78%) 0.05* 0.05 0.9399 to 20.4740 
No  2 (6%) 15 (22%)   
Can share or break 
ACT pack to sell 
     
Yes  9 (27%) 32 (47%) 0.0923 0.083 0.1712 to 1.0398 
No  24 (73%) 36 (53%)   
*Fishers’ exact test 
** Chi squared test 
 
Those vendors who had been trained in patent medicine regulations and practices by the 
Pharmacist Council of Nigeria were more likely to know the reason for the policy change 
than those who were not trained - 69% of those trained gave the correct reason compared 
to 43% who are untrained (p<0.05). Those who had attended PMV training were also 
more likely to ask for the specific age of the patient (84%) than those who were not 
trained (58%). However, more of those who had attended PMV training reported that CQ 
is still used for malaria treatment (90%) compared to those not trained (63%). A 
surprising finding was that those who had attended PMV training were less likely (16%) 
to have received training on the ACT policy than those who had not received training 
(46%) (Table 7). 
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Table 7: Comparison of medicine vendor training with knowledge of ACT Policy, 
and self-reported practices in the use of ACTs (N=101) 
 
*Fishers’ exact test 
** chi square 
 
Variable PMV- training DF P-value OR 95% CI 
 Yes  No      
Awareness 
of policy 
      
Yes 77 (76%) 2 (50%)     
No 24 (24%) 2 (50%) 1 0.255* 0.3117 0.0416 to 
2.3329 
Reason for 
change in 
policy 
      
Additional 
drug to CQ 
24 (31%) 14 (58%) 1 0.031** 0.3235 0.1258 to 
0.8313 
ACTs more 
potent 
53 (69%) 10 (43%)    
Training on 
policy 
      
Yes 12 (16%) 11 (46%) 1 0.006** 0.2251 0.0818 to 
0.6198 No 63 (84%) 13 (54%)    
 Yes  No      
Asks for age 
of user 
      
Yes  59 (84%) 18 (58%) 1 0.009** 3.8737 1.4819 to 
10.1259 
No  11 (16%) 13 (42%)     
CQ still used 
in treatment 
of malaria 
      
Yes  69 (90%) 15 (63%) 1 0.005** 5.1750 1.7157 to 
15.6089 No 8 (10%) 9 (38%)    
Can share or 
break ACT 
pack to sell 
      
Yes  27 (35%) 14 (58%) 1 0.0737 0.3857 0.1511 to 
0.9843 No  50 (65%) 10 (42%)    
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Training on the ACT policy did not seem to improve the PMVs understanding of the 
reason why the ACT policy was introduced or have a positive impact on some of the self-
reported practices in the use of ACTs (Table 8). Less of those trained (57%) in the ACT 
policy gave the correct reason for the change compared to those who had not received 
training on the policy (64%)  Training on the ACT policy was found to be associated with 
self-reported practices in the use of ACT such as sharing or breaking the pack of ACT to 
sell - surprisingly more of those trained on the policy reported that they could share the 
ACT pack (78%) compared to those not trained (29%). It was also found that less (22%) 
of those who attended the ACT training asked the age of the user, than those who did not 
attend the training (83%). One area in which attendance at the ACT training did have a 
positive impact was in the discontinuance of the use of chloroquine in treating malaria. 
Table 8: Comparison of training on ACT policy with understanding of ACT Policy 
and practices in the use of ACTs (N=101) 
 
Variable TRAINING ON ACT POLICY 
DF P-value OR 95% CI 
 YES NO     
Reason 
policy was 
introduced 
      
Additional 
drug in CQ 
10 (43%) 28 (36%) 1 0.6784 1.3736 0.5337 to 
3.5353 
ACTs more 
potent 
13 (57%) 50 (64%)     
Can share 
ACT pack 
      
Yes  18 (78%) 23 (29%) 1 0.0001*
* 
8.6087 2.8544 to 
25.9632 
No  5 (22%) 55 (21%)    
Ask for 
age of user 
      
Yes  5 (22%) 65 (83%) 1 0.0001* 0.0556 0.0175 to 
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* 0.1765 
No  18 (78%) 13 (17%)    
CQ still 
used in 
malaria 
treatment 
      
Yes  9 (39%) 75 (96%) 1 0.0001* 0.0257 0.0062 to 
0.1070 
No  14 (61%) 3 (4%)     
*Fishers’ exact test 
** chi square 
 
 
Table 9: Comparison of sex of patent medicine vendor training as a PMV and 
training on ACT policy  
 
Variable SEX DF P-value OR 95% CI 
 FEMALE MALE     
Training 
on ACT 
policy 
(N=101) 
      
Yes  6 (26%) 17 (22%) 1 0.8820 1.2664 0.4323 
to 
3.7099 
No  17 (74%) 61 (78)    
PMV 
training 
(N=105) 
      
Yes  18 (78%) 61 (74%) 1 0.9150 1.2393 0.4093 
to 
3.7531 
No  5 (22%) 21 (26%)    
 
 
Gender did not seem to be a factor as to whether a PMV received training as a PMV or 
on the ACT policy, with 26% of females reporting that they had received ACT training 
compared with 22% of males.  
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5.2: DISCUSSION  
 
This study sought to describe and quantify the knowledge and practices of patent 
medicine vendors, in an urban area of Lagos, in the use of ACTs and to assess these 
against the National Artemisinin-based combination therapy Anti-malaria Treatment 
Policy (FMOH, 2005a). A large percentage of medicines used in home management of 
malaria in Nigeria are obtained from patent medicine vendors. Prompt and appropriate 
home management of malaria is one of the cornerstones of malaria control. 
 
5.2.1: Knowledge of symptoms of uncomplicated and severe malaria.   
Malaria is endemic in Nigeria and a common condition amongst the populace. It is 
therefore expected that the medicine vendors would have adequate experience 
recognizing the symptoms. The results of this study showed that the knowledge of the 
symptoms of malaria was very high.  This is congruent with results of other studies which 
indicate that knowledge of the symptoms of malaria is high in endemic areas (Aikens, 
Pickering & Greenweed, 1994).  However, only 11% mentioned convulsions which are 
the most important signs to recognize severe malaria. A critical condition for referral to a 
treatment facility or clinic is severe malaria or when or there is a lack of improvement 
(FMOH, 2005). Surprisingly, 74% of PMVs correctly reported that they would refer 
severe malaria to a treatment facility; however, given the poor recognition of identifying 
severe malaria, it is doubtful that adequate referral is occurring in this practice setting. 
This issue needs to be addressed as high mortality due to severe malaria is likely 
especially amongst children and pregnant women.  
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The medicine vendors in this community would benefit from training and educational 
interventions geared towards the improvement of the recognition of signs of severe 
malaria (Oshiname & Breiger, 1992).   
 
5.2.2: National ACT anti-malaria treatment policy  
Knowledge of existence of the ACT Anti-malaria Treatment Policy was high. There are, 
however, indications that understanding and application is weak with respect to choice of 
anti-malarial and appropriate use in specific groups such as pregnant women and 
children. The study showed that PMVs were not clear about what an ACT is, with only 
14% correctly naming two ACTs. At the same time 14% erroneously thought that 
artesunate, one component of the artemisinin based combination therapy, was an ACT. 
Responses to questions on the effectiveness of ACTs in comparison to CQ and SP 
monotherapy provided somewhat confused answers. All this seemed to indicate that 
PMVs do not have a good understanding of the reasons for the new policy and thus it is 
not surprising that their practices in the choice of anti-malarial drugs deviate from the 
policy guidelines. This is worrying because supply of the wrong medicines will increase 
sickness and fatalities due to malaria and also the rapid emergence of drug resistance.    
 
Over two thirds of PMVs indicated that they obtained information on the policy from 
representatives of drug manufacturers and only 4% got the information from government 
sources. A number of studies have provided evidence that information from medical 
representatives of drug companies is usually distorted, which in this case could mean 
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providing inadequate or incorrect information as to what constitutes an ACT (Bardeley, 
Becel, Hoen, 1998). The Federal Ministry of Health (FMOH) is responsible for 
formulating and ensuring compliance to this policy. The report of the policy 
implementation indicates that various methods were used, to disseminate information on 
the change from chloroquine to ACT. These channels included seminars workshops, 
advocacy visits to communities, decision makers and relevant profession groups 
including patent medicine vendors. However the level of knowledge of PMVs from this 
study sample seems to indicate that the government strategies and programmes to 
disseminate information and implement the policy were inadequate and unsuccessful. 
This may also be a reflection of the documented constraints and complexities that have 
been identified in changing and implementing a drug policy change (Zurovac, et al, 2005; 
Amin, et al, 2007). Some of these constraints include the availability of the former drug 
of choice in the market (chloroquine in the case of Nigeria). This can be attributed to a 
lack of political will power and anecdotal report of continued effectiveness and the 
adverse drug reactions associated with some of the ACTs especially artesunate 
amodiaquine.   
 
5.2.3: Anti-malaria treatment Practices  
Practices are of great significance especially in the case of childhood malaria as 
inappropriate or ineffective drugs or the use of wrong dosages can lead to death within 
48hours of onset of illness (Greenwood, et al, 1997). Although chloroquine and SP are no 
longer recommended for use in malaria treatment in Nigeria, the study found that 55% 
and 71% of the medicine vendors are still using CQ and SP, respectively, In fact, in the 
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two months prior to the study over fifty percent of the medicine vendors ranked 
chloroquine as the most frequently supplied anti-malarial, with only 16% reporting ACTs 
as the most frequently supplied. 
 
Furthermore it was observed that the most important factors in determining the choice of 
anti-malarial supplied by the vendors in this community was “what the customer requests 
for”. This was followed by cost; availability of anti-malarial; and fourthly by government 
policy. This is congruent with findings of other studies in which patient and caregivers 
requests were of high importance (Ongore & Nyabola, 1996; Oshiname & Breiger, 1992; 
Adome, 1996). This would seem to suggest that in order to improve home management 
of malaria, and to realize the impact of the ACT policy, there is a need for community 
level re-orientation on drug use and policy information dissemination to 
mothers/caregivers. This may be challenging as it would require an understanding of the 
social, cultural and other factors that influence and determine drug choice and use 
(Djimide et al, 1998).  Interestingly however, research results have indicated that 
mothers/caregivers would take the advice of vendors if they perceive them as adequately 
trained by a credible health authority (Marsh et al, 1999; Marsh et al, 2004). This type of 
intervention can therefore be explored in this setting to improve community drug use.  
 
The second most important factor determining the choice of anti-malarial medication was 
“cost”. High ACT prices have been identified as a major barrier to usage in the private 
sector (Gilpin, 2008). ACTs cost N504 (US$4.03) for a treatment dose, which is 
considerably more expensive than the other anti-malarials such as chloroquine which 
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costs about N83 (US $ 0.66) and Sulfadoxine Pyrimethamine which costs about N91 (US 
0.73) (Oladepo et al, 2007). This means the ACTs cannot be afforded by the poor, the 
socio-economic strata that is frequently sick with malaria (Barat et al, 2004, 
WHO/SEARO, 2002). 
 
To address this issue of affordability, several initiatives are been put in place especially in 
the public sector, such as the Global fund for AIDs, Tuberculosis and malaria (GFATM). 
The Global fund has done a lot to ensure adequate supply of ACTs to the public/formal 
sector. Such programmes are currently not available in the private and informal sector 
hence the significance and relevance of the, Affordable Medicines Facility - malaria 
initiative (AM-Fm) by the Roll Back Malaria Coalition.  The goal of this initiative is to 
reduce consumer prices to an affordable level, through a financing mechanism so that 
ACTs are available at about the same price as chloroquine. It is expected that with the 
successful implementation of this program, ACTs will be available through the formal 
and informal drug supply chain including medicine vendors, so ACTs can reach the 
poorest of the poor at an affordable price (Gilpin, 2008).   
 
The practice of selling oral artesuante monotherapy by these vendors further underscore 
the difficulty and complexities in the successful implementation of a new drug policy 
when the transition involves a familiar drug which is available, effective and inexpensive 
such as artesunate in this case (Williams, et al, 2004; Zurovac, et al, 2005). The observed 
practices in this setting is also consistent with that of other studies which have 
documented practices of medicine vendor practices which are different from the national 
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treatment guidelines (Battersby, et al, 2003; Djimide et al, 1998).  However, there is 
evidence from a number of countries that training medicine sellers resulted in improved 
adherence to policy guidelines (Marsh et al, 2004, Greer et al, 2004).   
 
5.2.4: Regulation of Patent Medicine Vendors 
This study also revealed other illegal practices by PMVs, such as the stocking and sale of  
chloroquine and sulfadoxine-pyrimethamine monotherapy for the treatment of malaria.  
CQ and SP have both been re-categorized as prescription only medicines for use in the 
treatment of amoebiasis, and intermittent preventive treatment (IPT) of malaria in 
pregnant women, respectively. So PMVs are not allowed to stock or sell these medicines 
anymore. This practice of stocking prescription only medicines (POM) has also been 
widely documented by other studies in similar settings (Oshiname & Breiger, 1992; 
Fassin, 1998). The weak regulation of PMVs may be partly responsible for the observed 
practices. In recent times, regulatory activities by the Pharmacists’ Council of Nigeria 
(PCN) and NAFDAC have been weak and ineffective due to administrative bottlenecks. 
This has created an environment for practices that mitigate against the success of the 
policy, if allowed to go unhindered. The findings of this study point to the need of 
increased regulatory control of PMVs by both the PCN and NAFDAC. 
 
The study results also indicates that the ACT policy training may not have achieved the 
desired goal to enlighten PMVs on the policy and use of ACTs . This is in view of the 
fact that more of those trained on the policy report that ACTs can be shared and are less 
likely to ask for the age of the user. This is interesting and may require further 
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exploration because it may be an indication that the training was either inadequate or a 
refresher course is urgently required. Vendors with secondary or tertiary education were 
more likely to be trained. This may seem to suggest a perception that training organizers 
prefer to train vendors with a higher educational qualification. Currently the educational 
requirement to qualify for a patent and proprietary medicine vendors’ license (PPMVL) is 
not explicit, only the ability to read and write is required and an unverifiable proof of 
“good character”.  This study also shows that 4% of respondents had no formal education 
and by convention primary school education has been found adequate. These results seem 
to suggest that the PCN should reconsider the educational qualification stipulations for 
granting a PPMVL. 
 
Patent medicine vendors fill a very critical gap in the health delivery system and in the 
treatment of malaria and febrile illnesses (Salami & Breiger, 2005).Whilst it has been 
argued that widespread use of anti-malarials in the hands of non-medical personnel could 
lead to inappropriate use and the rapid emergence of resistance; evidence exists that if 
mothers/caregivers, community volunteers, shopkeepers, school teachers and drugs 
vendors are trained, they can use anti-malarials appropriately. It is the lack of training or 
information that leads to inappropriate use (WHO, 2004).  
 
Studies regarding the practices  and relevance of PMVs have often recommended a role 
expansion. Some members of the healthcare profession have however argued against this 
claiming it would erode the functions and position of the pharmacist. This is unlikely to 
be the case as the there are over 200,000 patent medicine vendors in Nigeria and only 
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about 12,000 pharmacists and most practice in the urban areas. The communities in the 
rural areas depend solely on these  medicine vendors for their health needs and health 
information, since the public health facilities cannot be accessed by them for reasons 
including; distance, cost, stock outs restricted operating times and the unfriendly nature 
of hospital staff. (Snow, et al 1992; Williams & Jones, 2004). 
 
This study identified a number of deficiencies in the current knowledge and practices of 
PMVs regarding the ACT anti-malarial policy. The Pharmacist Council of Nigeria 
(PCN), NAFDAC and the Federal Ministry of Health (FMOH) who have over-sight 
functions, in terms of policy formulation, implementation and regulating the activities of 
the PMVs should take the lead in training, information dissemination and regulation to 
ensure optimal implementation of the national ACT anti-malarial treatment policy.  
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CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
6.1: Conclusions  
This study found that PMVs with correct knowledge of the symptoms of malaria was 
high, but knowledge of the signs of severe malaria was inadequate. 
 
The medicine vendors in this study had a high awareness of the ACT anti-malarial 
treatment policy but exhibited an inadequate understanding and application of the policy 
guidelines in their self-reported practices. 
  
Medicine vendors were engaged in practices which were counter-productive to the 
success of the policy, and malaria control in general, such as the continued use of 
chloroquine monotherapy, oral artesunate monotherapy and SP in the treatment of 
malaria; giving incorrect dosing information; and breaking or sharing the ACT pack to 
sell which could lead to sub-optimal doses and treatment failures. These indicate an 
urgent need for educational interventions and behaviour change communication (BCC) 
for PMVs and caregivers in the community.  
 
Finally, the policy implementers NAFDAC and PCN need to scale up monitoring, 
supervisory and capacity building activities of the medicine vendors to ensure optimal 
implementation of  the ACT anti-malarial policy guidelines. 
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6.2: Recommendations 
The results of the research study identified a number of key areas that need to be 
addressed in order to ensure optimal management of malaria in this setting.  
 
• There is an urgent need for educational interventions to improve knowledge and 
ensure practices are in line with ACT anti-malaria policy guidelines.  
 
• There should be a re-orientation and community-based health education 
programme to improve the knowledge of mothers/caregivers about the policy, so 
that they can make informed choices when choosing anti-malarials and improve 
the home management of malaria. 
 
• The PCN and NAFDAC should improve regulatory control of PMVs to ensure 
adherence to the ACT policy.   
 
• NAFDAC should encourage the gradual phasing out of co-blistered formulations 
of ACTs and permit the sale of only fixed dose combination to prevent 
monotherapy and wrong dosage through breaking or sharing the ACT pack. In 
addition, there should be a scale up of continuous campaign against oral 
artesunate monotherapy and other monotherapies including chloroquine, SP and 
the other anti-malarials to prevent the development of resistance to ACTs. 
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• The Roll Back Malaria partnership (RBM) and the Federal Ministry of Health 
should speed up the implementation of  Affordable Medicines Facility –malaria 
(AM-FM) initiative to provide safe, efficacious and affordable ACTs. 
 
• Future studies in this regard, should assess and the knowledge and practices of 
licensed and unlicensed PMVs and other health care professionals, for example 
doctors and pharmacists.  
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APPENDICES 
APPENDIX 1: DATA COLLECTION TOOL 
 
DATA COLLECTION TOOL 
 
Thesis Title: Knowledge and practices of patent medicine vendors (PMVs) on the use 
of Artemisinin combination therapies (ACTs) in an urban community 
Lagos. 
Name of Interviewer:……………..      Date:…………….. Questionnaire No: ………… 
 
A. DEMOGRAPHIC INFORMATION: 
 
(1) Sex :      (1) Male                   (2) Female 
(2) Age    
(3) What is your highest level of education?  
(i).     Tertiary.                    (ii).     Senior Secondary School 
           (iii).   Primary School                           (iv).    No formal Education. 
(4)        How long have you worked as a PMV?    
 
(5A) Have you had any training at all as a patent medicine vendor? Yes  No  
(5B)If yes give details 
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Name of 
the course 
attended  
When (date) How long 
(total 
number of  
hours or 
days) 
List all topics 
covered 
Name of 
Training 
Provider 
Who 
organized the 
training? 
      
      
 
 
(5C)Have you attended any training on Malaria in the past 3 years? Yes              No     
5D)If yes give detail;  
 
Name of 
the course 
attended  
When (date) How long 
(total 
number of  
hours or 
days) 
List all topics 
covered 
Name of 
Training 
Provider 
Who 
organized the 
training? 
      
      
 
B. Knowledge of Signs and Symptoms of Malaria: 
 
(6).  what do you think are the major symptoms of malaria?  (tick the correct ones) 
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                                                                                Yes     No 
Hotness of the body/high temperature…………… 1           2 
Dark coloured Urine……………………………….1          2 
Joint pains………………………………………… 1          2 
Headache…………………………………………..1           2 
Loss of appetite…………………………………….1          2 
Vomiting…………………………………………...1          2 
Weakness/Dizziness……………………………… 1          2 
Cold/rigors                                                                1          2 
Others (Specify) [                         ]………………...1          
Others (Specify) [                          ]……….……   ..1 
Don’t know [                          ]…………….………1 
   
 
(7). How do you know when someone has severe malaria (pls tick all that is correct) 
                                                                   Yes     No 
Hotness of the body/high temperature........1          2 
Dark coloured Urine……………………...1          2 
Joint pains………………………………...1          2 
Headache………………………………....1           2 
Loss of appetite………………………….. 1          2 
Vomiting………………………………….1          2 
Weakness/Dizziness…………………........1         2 
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Convulsions……………………………….1         2 
Anaemia.......…………………………....…1         2  
Others (specify) [                          ]………..1 
 
(8) In what condition do you think a child with malaria should be referred to the clinic? 
(multiple codes allowed, do not read out )  
 
                                                                                                Yes      No 
No improvement after completing malaria treatment...............1          2 
Severe malaria...........................................................................1          2 
Others , specify..........................................................................1      
                        
C.        Knowledge Of The Artemisinin based combination therapy (ACT)  
 
(9)   Are you aware of the new government Artemisinin based combination therapy 
(ACT)     
       policy in the treatment of malaria?   Yes.                   No. 
 
(10) If yes, where did you get the information? (tick main source )_ 
              (i) Government sources   
             (ii) Drug manufacturers/distributors  
              (ii) PMV association                            
              (iv) Others    (specify)                                                    
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(11) Why do you think this new policy was introduced?  
(i)An additional drug to chloroquine in malaria ttreatment     
(ii) ACTs are more potent and better to treat malaria     
(iii) I don’t know      
 
(12) Have you had any training on the ACT policy? 
Yes                   No   
 (13) Can you name two ACT antimalarial drugs?  
1…………………………..2……………………………… 
(14)   When did you start selling ACTs to your customers? (tick one box) 
     (i) 2005                ii) 2006            (ii) 2007                   (iv) 2008                                                      
 
(15)  Are ACTs suitable for use by: 
      Pregnant women         Yes                          No                     don’t know 
      Breast feeding mothers Yes                       No                        don’t know      
      
 (16) What is the recommended use of sulfadoxine/pyrimethamine now (for example 
Fansidar, tick one only)? 
(i) IPT              
(ii) Second line to chloroquine   
(iii)Don’t know  
(iv) Others (specify) ………………….. 
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(17) Is chloroquine still used in the treatment of malaria? 
   Yes                      No                                don’t know         
  
(18) How do you rate the effectiveness of ACTs compared to other antimalarials such as 
chloroquine or fansidar (tick one box). 
(A) chloroquine 
(i) ACTs are more effective than chloroquine     
(ii) ACTs have the same effectiveness as chloroquine     
(iii) ACTs are less effective than chloroquine 
(iv)   Don’t know          
 
(B) Fansidar 
(i) ACTs are more effective than fansidar    
(ii) ACTs have the same effectiveness as fansidar     
(iii) ACTs are less effective than fansidar     
(iv)  Don’t know                                                   
 
D. Current Practices In The Use Of ACT In Treatment Of Malaria 
Use of ACTs: 
(19) Do you currently sell chloroquine and fansidar to treat malaria? 
chloroquine Yes                        No   
  fansidar        Yes                         No      
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(20)   In the past 2 months, which antimalaria drug have you most frequently 
recommended? (rank 1 -4 with one as the most recommended) 
(i) CQ                                (ii) SP              (iii)ACTs              (iv)Halofantrine                  
(v)    others (specify) 
  
 (21)    What determines which antimalaria drugs you sell to your customers? ( rank these 
reasons 1-4, 1 being the most important) 
 (i)  What they request for  (ii)    Cost      (iii) Availability of the   antimalaria drug  
. (iv) Govt policy (v)   others (specify)………………. 
 
(22) If a customer wishes to buy any ACT, can you share the pack or break the pack for 
sale to the customer: yes                                           No 
 
(23) Do you usually ask for the specific age of the user before selling ACT?   
Yes                       No       
 
(24) Do you explain the drug dosage to the customers? Yes                  No  
(25)If yes, pls give an  example of dosage for coartem: 
…………………………………………………………………….. 
ACTs Stock Control: 
 (26) What is your main source of ACTs anti-malaria drugs? (Main source only) 
(i)   Source from other outlets/pharmacy shops  
 
 
 
 
 81
(ii) Manufacturer    
(iii) Distributors  
(iv)   Others...…. (.specify) 
(27) Where do you store your ACT anti-malaria drugs? (tick all that apply ) 
                                                                      Yes            No 
Cool area on the shelf…….....................   1                 2 
Away from sunlight............... …      ...….1                 2 
A well ventilated area …….........……..  .1                 2 
In a enclosed glass shelf...........................1                 2 
Others (Specify) [                   ]……….... 1      
                 
(28) Do you think sunlight has any effect on ACT anti-malaria drugs? 
 Yes.                No   .            
APPENDIX 2: PARTICIPANT INFORMATION SHEET  
 
UNIVERSITY OF THE WESTERN CAPE 
School of Public Health 
Private Bag X 17, Bellville 7535, South Africa 
Tel: +27 21-959 2809, Fax: 27 21-9592872 
http://www.uwc.ac.za/comhealth/soph 
 
 
PARTICIPANT INFORMATION SHEET  
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Project Title:  Knowledge and practices of Patent Medicine Vendors (PMVs) in the use of 
Artemisinin based combination therapy (ACT) in an urban community in Lagos.  
 
What is this study about?  
This is a research project being conducted by Rametu Momodu, a MPH student at the 
University of the Western Cape, South Africa.  We are inviting you to participate in this 
research project because you are a patent medicine vendor in this community. The purpose of 
this research project is to determine your knowledge of ACTs and their usage in the 
treatment of malaria.  
 
What will I be asked to do if I agree to participate? 
You will be asked to provide some information about your background such as your, level of 
education, length of employment or practice as a patent medicine vendor, your knowledge of 
malaria, ACTs and your practice when attending to customers who come to purchase 
medicine for fever/malaria. 
  
Would my participation in this study be kept confidential? 
The survey is anonymous and will not contain information that may personally identify you. 
The result of the survey will be presented in an aggregated form which will not be traceable 
to any respondent.  
 
What are the risks of this research? 
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There are no risks associated with participating in this research project.   
 
 
What are the benefits of this research? 
The benefits to you include possible improvement in your knowledge and practice in the use 
of ACTs in malaria treatment and the care received by your customers. The results of this 
survey and recommendations for improvement will be presented to policy makers in the 
Federal Ministry of Health and the RollBack malaria committee.  
 
Do I have to be in this research and may I stop participating at any time?   
Your participation in this research is completely voluntary.  You may choose not to take part 
at all. If you decide to participate in this research, you may stop participating at any time 
without any reason.  If you decide not to participate in this study or if you stop participating 
at any time, you will not be penalized or lose any benefits. 
 
Is any assistance available if I am negatively affected by participating in this study? 
Since this study is not invasive, I do not anticipate any adverse effects of this study on you.  
 
What if I have questions? 
This research is being conducted by Rametu Momodu, School of Public Health, at the 
University of the Western Cape.  If you have any questions about the research study itself, 
please contact Rametu Momodu at: 71 Adisa Bashua Close, Surulere ,Lagos Nigeria, 
+2348033159778, rametu3@yahoo.com .Should you have any questions regarding this study 
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and your rights as a research participant or if you wish to report any problems you have 
experienced related to the study, please contact:   
 
Hazel Bradley  
University of the Western Cape 
Private Bag X17, Belville 7535 
Telephone: +2721 959-2630 
Cell: +27 72 297 9932 
Fax: (021) 959- 2872 
Email: hbradley@uwc.ac.za 
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APPENDIX 3: INFORMED CONSENT FORM 
UNIVERSITY OF THE WESTERN CAPE 
School of Public Health 
Private Bag X 17, Bellville 7535, South Africa 
Tel: +27 21-959 2809, Fax: 27 21-9592872 
http://www.uwc.ac.za/comhealth/soph 
 
INFORMED CONSENT FORM 
Title of Research Project: Assessment of the Knowledge and Practices of Patent Medicine 
vendors in the use of Artemisinin based combination therapy in an urban community in 
Lagos. 
  
I believe I have been properly informed and that I understand the nature and goals of the 
study. I freely and voluntarily agree to participate. My questions about the study have been 
answered. I understand that my identity will not be disclosed and that I may withdraw from 
the study without giving a reason at any time and this will not negatively affect me in any 
way.  
Participant’s name……………………….. 
Participant’s signature……………………………….                                   
Date……………………… 
Should you have any questions regarding this study or wish to report any problems you have 
experienced related to the study, please contact the study coordinator: 
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Rametu Momodu 
71, Adisa Bashua, Surulere 
Masha, Lagos 
Telephone: +1-8535824 
Cell: + 234-8033159778 
Email:rametu3@yahoo.com 
 
Supervisor: 
Hazel Bradley  
University of the Western Cape 
Private Bag X17, Belville 7535 
Telephone: +2721 959-2630 
Cell: +27 72 297 9932 
Fax: (021) 959- 2872 
Email: hbradley@uwc.ac.za 
 
 
 
 
 
